Stifel Canada Upgrades Cipher Pharmaceuticals (TSE:CPH) to Strong-Buy

Stifel Canada upgraded shares of Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) from a hold rating to a strong-buy rating in a research report sent to investors on Monday, Zacks.com reports. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ Q3 2024 earnings at $0.25 EPS, Q4 2024 earnings at $0.22 EPS and FY2024 earnings at $0.90 EPS.

Separately, Stifel Nicolaus raised shares of Cipher Pharmaceuticals from a hold rating to a buy rating and boosted their price target for the stock from C$9.50 to C$16.00 in a report on Tuesday.

Cipher Pharmaceuticals Stock Performance

Shares of Cipher Pharmaceuticals stock opened at C$13.85 on Monday. The firm has a market capitalization of C$333.92 million, a P/E ratio of 11.26 and a beta of 1.05. The company has a current ratio of 7.96, a quick ratio of 2.67 and a debt-to-equity ratio of 0.38. The business’s fifty day simple moving average is C$9.61 and its 200 day simple moving average is C$8.63. Cipher Pharmaceuticals has a 12 month low of C$3.52 and a 12 month high of C$14.55.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.